高通量脑脊液蛋白质组学与机器学习识别帕金森病发生与进展的蛋白质组特征
本研究基于帕金森病进展标志物计划(PPMI)的国际多中心数据,利用适配体脑脊液蛋白质组学(4,071种蛋白)和机器学习方法,在279例非遗传性帕金森病患者与141例健康对照中构建了帕金森病蛋白质组评分(PD-ProS),并在内部验证队列及LRRK2队列联盟中验证其区分能力,同时发现该评分可独立预测帕金森病患者的认知与运动功能下降。
要点
- 基于14种差异表达蛋白构建的PD-ProS区分非遗传性帕金森病与健康对照的AUC为0.83(95%CI 0.78-0.87)。
- 在LRRK2队列联盟中,仅5种共有蛋白以相同权重区分非遗传性帕金森病与健康对照的AUC为0.75(95%CI 0.63-0.87)。
- PD-ProS可独立预测帕金森病患者的痴呆(aHR-Q5 2.8,95%CI 1.6-5.0)和Hoehn-Yahr IV期(aHR-Q5 2.1,95%CI 1.1-4.0)。
核心结论
- 整合高通量蛋白质组学与机器学习识别出的脑脊液蛋白质组特征对帕金森病的发生和进展具有重要临床价值。
研究设计与样本
- 观察性研究,使用帕金森病进展标志物计划(PPMI)在国际中心入组的帕金森病患者、健康对照及携带GBA1、LRRK2和/或SNCA致病变异的非帕金森病参与者(遗传性前驱期)数据。
- 基于适配体脑脊液蛋白质组学数据(定量4,071种蛋白)筛选参与者,并分为非遗传性帕金森病、健康对照、遗传性帕金森病和遗传性前驱期四类。
- 对非遗传性帕金森病与健康对照数据行差异表达蛋白分析与最小绝对收缩和选择算子(LASSO)建模,构建PD-ProS,并在内部验证后用LRRK2队列联盟(LCC)的1,556种脑脊液蛋白数据进行外部验证。
- 进一步在遗传性帕金森病和遗传性前驱期受试者中检验PD-ProS,并分析其与临床进展的关联。
主要发现
- PD-ProS推导队列纳入279例非遗传性帕金森病患者(平均±标准差年龄62.0±9.6岁;男性67.7%)和141例健康对照(年龄60.5±11.9岁;男性64.5%)。
- 从23种差异表达蛋白中,LASSO确定14种蛋白的权重用于PD-ProS,其区分非遗传性帕金森病与健康对照的AUC为0.83(95%CI 0.78-0.87)。
- 在独立内部验证队列(71例非遗传性帕金森病患者和35例健康对照)中,PD-ProS的AUC为0.81(95%CI 0.73-0.90)。
- 在LCC中,14种差异表达蛋白中仅5种也被测定,这5种蛋白以相同权重区分34例非遗传性帕金森病患者与31例健康对照的AUC为0.75(95%CI 0.63-0.87)。
- PD-ProS可区分258例遗传性帕金森病患者与365例遗传性前驱期参与者;无论遗传状态如何,PD-ProS独立预测帕金森病的认知和运动功能下降(痴呆:最高五分位调整风险比[aHR-Q5] 2.8,95%CI 1.6-5.0;Hoehn-Yahr IV期:aHR-Q5 2.1,95%CI 1.1-4.0)。
关键数值与推荐
- PD-ProS区分非遗传性帕金森病与健康对照的AUC为0.83(95%CI 0.78-0.87)。
- 内部验证队列中PD-ProS的AUC为0.81(95%CI 0.73-0.90)。
- LCC中5种共有蛋白以相同权重区分非遗传性帕金森病与健康对照的AUC为0.75(95%CI 0.63-0.87)。
- PD-ProS预测痴呆的aHR-Q5为2.8(95%CI 1.6-5.0),预测Hoehn-Yahr IV期的aHR-Q5为2.1(95%CI 1.1-4.0)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: This study aimed to identify CSF proteomic signatures characteristic of Parkinson disease (PD) and evaluate their clinical utility. METHODS: This observational study used data from the Parkinson's Progression Markers Initiative (PPMI), which enrolled patients with PD, healthy controls (HCs), and non-PD participants carrying GBA1, LRRK2, and/or SNCA pathogenic variants (genetic prodromals) at international sites. Study participants were chosen from PPMI enrollees based on the availability of aptamer-based CSF proteomic data, quantifying 4,071 proteins, and classified as patients with PD without GBA1, LRRK2, and/or SNCA pathogenic variants (nongenetic PD), HCs, patients with PD carrying the aforementioned pathogenic variants (genetic PD), or genetic prodromals. Differentially expressed protein (DEP) analysis and the least absolute shrinkage and selection operator (LASSO) were applied to the data from nongenetic PD and HCs. Signatures characteristics of nongenetic PD were quantified as a PD proteomic score (PD-ProS), validated internally and then externally using data of 1,556 CSF proteins from the LRRK2 Cohort Consortium (LCC). We further tested the PD-ProS in genetic PD and genetic prodromals and examined associations with clinical progression. RESULTS: Data from 279 patients with nongenetic PD (mean ± SD, age 62.0 ± 9.6 years; male 67.7%) and 141 HCs (age 60.5 ± 11.9 years; male 64.5%) were used for PD-ProS derivation. From 23 DEPs, LASSO determined weights of 14 DEPs for the PD-ProS (area under the curve [AUC] 0.83, 95% CI 0.78-0.87), validated in an independent internal validation cohort of 71 patients with nongenetic PD and 35 HCs (AUC 0.81, 95% CI 0.73-0.90). In the LCC, only 5 of the 14 DEPs were also measured. Notably, these 5 DEPs still distinguished 34 patients with nongenetic PD from 31 HCs with the same weights (AUC 0.75, 95% CI 0.63-0.87). Furthermore, the PD-ProS distinguished 258 patients with genetic PD from 365 genetic prodromals. Finally, regardless of genetic status, the PD-ProS independently predicted both cognitive and motor decline in PD (dementia, adjusted hazard ratio in the highest quintile [aHR-Q5] 2.8 [95% CI 1.6-5.0]; Hoehn and Yahr stage IV, aHR-Q5 2.1 [95% CI 1.1-4.0]). DISCUSSION: By integrating high-throughput proteomics with machine learning, we identified PD-associated CSF proteomic signatures crucial for PD development and progression. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov (NCT01176565). A link to the trial registry page is clinicaltrials.gov/ct2/show/NCT01141023. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that the CSF proteome contains clinically important information regarding the development and progression of Parkinson disease that can be deciphered by a combination of high-throughput proteomics and machine learning.
引用
- Tsukita K, Sakamaki-Tsukita H, Kaiser S, et al. High-Throughput CSF Proteomics and Machine Learning to Identify Proteomic Signatures for Parkinson Disease Development and Progression. Neurology. 2023. PMID: 37586882. doi:10.1212/WNL.0000000000207725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。